v3.26.1
Note 7 - Segment Reporting
 3 Months Ended
Mar. 31, 2026
Notes to Financial Statements  
Segment Reporting [Text Block]

Note 7 - Segment Reporting

 

Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single segment (the “Segment”) for the purposes of assessing performance and making operating decisions. The CODM of the Segment is the Company’s Chief Executive Officer. The Segment is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs. The accounting policies for the Segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The CODM assesses the performance of the Segment and decides how to allocate resources based on net loss that is reported on the condensed consolidated statements of operations. Further, the following represents information about Segment loss and significant Segment expenses:

 

  

Three Months Ended

 
  

March 31,

 
  

2026

  

2025

 

Revenues

 $—  $— 

Less:

        

Clinical and regulatory

  1,690,402   1,706,705 

Manufacturing

  612,212   483,065 

Research

  408,834   308,327 

General and administrative support

  1,664,101   1,286,422 

Non-cash expenses(1)

  118,635   184,773 

Other income

  31,748   4,771 

Plus:

        

Realized and unrealized gain (loss)

  541   (80)

Segment and net loss

 $4,461,895  $3,964,601 

 

(1) Includes $118,634 and $184,773 of stock-based compensation expense for the three months ended  March 31, 2026 and 2025, respectively.